• Citer

Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.

par Fumagalli, Debora ;Salgado, Roberto;Criscitiello, Carmen ;Pugliano, Lina ;Laïos, Ioanna;Wilson, T. A.;Larsimont, Denis ;Piccart-Gebhart, Martine ;Michiels, Stefan ;Lackner, Mark;Sotiriou, Christos ;Loi, Sherene
Référence ASCO Annual Meeting (2013-06: Chicago, USA)
Publication Non publié, 2016-06

Communication à un colloque

• Détails

Titre:	Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.
Auteur:	Fumagalli, Debora; Salgado, Roberto; Criscitiello, Carmen; Pugliano, Lina; Laïos, Ioanna; Wilson, T. A.; Larsimont, Denis; Piccart-Gebhart, Martine; Michiels, Stefan; Lackner, Mark; Sotiriou, Christos; Loi, Sherene
Informations sur la publication:	ASCO Annual Meeting (2013-06: Chicago, USA)
Statut de publication:	Non publié, 2016-06
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Langue:	Anglais